Tags

Type your tag names separated by a space and hit enter

The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer.
Breast Cancer Res Treat. 2003 Mar; 78(2):149-58.BC

Abstract

BACKGROUND

Many members of the human kallikrein gene family were found to be differentially expressed in various malignancies and some of them are useful diagnostic/prognostic markers. KLK9 is a newly discovered human kallikrein gene that is expressed in several tissues including thymus, spinal cord, testis, prostate, breast, and ovary. Like other kallikreins, the KLK9 gene was found to be regulated by steroid hormones, mainly estrogens and progestins, in cancer cell lines.

EXPERIMENTAL DESIGN

We studied the expression of KLK9 by quantitative RT-PCR in 169 breast cancer patients of different stages, grades and histological types. We also compared the relation between KLK9 expression and other clinicopathological variables and patient survival.

RESULTS

KLK9 expression is significantly higher in patients with early stage cancers (p = 0.039) and in patients with small tumor size (< 2 cm) (p = 0.028). Kaplan-Meier survival curves demonstrated that KLK9-positive patients have longer disease-free and overall survival (p = 0.015 and 0.036, respectively). Univariate and multivariate analysis also indicates that KLK9 expression is associated with increased disease-free and overall survival. When the Cox proportional hazard regression analysis was applied to subgroups of patients, KLK9 expression was found to be a significant predictor of disease-free survival in the estrogen receptor (ER) and progesterone receptor (PR) negative subgroups of patients (Hazard Ratio 'HR' = 0.28, and 0.38, respectively, and p = 0.011 and 0.028, respectively). After adjusting for other known prognostic variables, KLK9 retained its independent prognostic value in these subgroups of patients. Similar results were obtained for overall survival.

CONCLUSIONS

KLK9 is a new potential independent marker of favorable prognosis in breast cancer.

Authors+Show Affiliations

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12725415

Citation

Yousef, George M., et al. "The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer." Breast Cancer Research and Treatment, vol. 78, no. 2, 2003, pp. 149-58.
Yousef GM, Scorilas A, Nakamura T, et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat. 2003;78(2):149-58.
Yousef, G. M., Scorilas, A., Nakamura, T., Ellatif, M. A., Ponzone, R., Biglia, N., Maggiorotto, F., Roagna, R., Sismondi, P., & Diamandis, E. P. (2003). The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Research and Treatment, 78(2), 149-58.
Yousef GM, et al. The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer. Breast Cancer Res Treat. 2003;78(2):149-58. PubMed PMID: 12725415.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. AU - Yousef,George M, AU - Scorilas,Andreas, AU - Nakamura,Terukazu, AU - Ellatif,Mohamed Abd, AU - Ponzone,Riccardo, AU - Biglia,Nicoletta, AU - Maggiorotto,Furio, AU - Roagna,Riccardo, AU - Sismondi,Piero, AU - Diamandis,Eleftherios P, PY - 2003/5/3/pubmed PY - 2003/11/13/medline PY - 2003/5/3/entrez SP - 149 EP - 58 JF - Breast cancer research and treatment JO - Breast Cancer Res Treat VL - 78 IS - 2 N2 - BACKGROUND: Many members of the human kallikrein gene family were found to be differentially expressed in various malignancies and some of them are useful diagnostic/prognostic markers. KLK9 is a newly discovered human kallikrein gene that is expressed in several tissues including thymus, spinal cord, testis, prostate, breast, and ovary. Like other kallikreins, the KLK9 gene was found to be regulated by steroid hormones, mainly estrogens and progestins, in cancer cell lines. EXPERIMENTAL DESIGN: We studied the expression of KLK9 by quantitative RT-PCR in 169 breast cancer patients of different stages, grades and histological types. We also compared the relation between KLK9 expression and other clinicopathological variables and patient survival. RESULTS: KLK9 expression is significantly higher in patients with early stage cancers (p = 0.039) and in patients with small tumor size (< 2 cm) (p = 0.028). Kaplan-Meier survival curves demonstrated that KLK9-positive patients have longer disease-free and overall survival (p = 0.015 and 0.036, respectively). Univariate and multivariate analysis also indicates that KLK9 expression is associated with increased disease-free and overall survival. When the Cox proportional hazard regression analysis was applied to subgroups of patients, KLK9 expression was found to be a significant predictor of disease-free survival in the estrogen receptor (ER) and progesterone receptor (PR) negative subgroups of patients (Hazard Ratio 'HR' = 0.28, and 0.38, respectively, and p = 0.011 and 0.028, respectively). After adjusting for other known prognostic variables, KLK9 retained its independent prognostic value in these subgroups of patients. Similar results were obtained for overall survival. CONCLUSIONS: KLK9 is a new potential independent marker of favorable prognosis in breast cancer. SN - 0167-6806 UR - https://www.unboundmedicine.com/medline/citation/12725415/The_prognostic_value_of_the_human_kallikrein_gene_9__KLK9__in_breast_cancer_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=12725415.ui DB - PRIME DP - Unbound Medicine ER -